# AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

> **NCT01654822** · PHASE2 · UNKNOWN · sponsor: **Cesa Projects International** · enrollment: 100 (estimated)

## Conditions studied

- Genital Human Papilloma Virus Infection

## Interventions

- **DRUG:** topical application cervical spray
- **DRUG:** topical spray on the cervix
- **PROCEDURE:** cervical swab with Cervex-Brush-Combi at T0
- **PROCEDURE:** cervical swab with Cervex-Brush-Combi at T1
- **PROCEDURE:** cervical swab with Cervex-Brush-Combi at T0
- **PROCEDURE:** cervical swab with Cervex-Brush-Combi at T1

## Key facts

- **NCT ID:** NCT01654822
- **Lead sponsor:** Cesa Projects International
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01654822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01654822, "AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01654822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*